Skip to main content

Table 1 Summary of six cases of leukemia with NUP98-PMX1 rearrangement

From: First case report of a NUP98-PMX1 rearrangement in de novo acute myeloid leukemia and literature review

Case no

Year

Sex

Age (years)

Primary diagnosis

Current diagnosis

Karyotype

Treatment

Outcome

References

1

1999

M

55

NHL stage III, gastric cancer

t-AML

46,XY,t(1;11)(q23;p15)

Topo II inhibitor; MACOP-B

Dead

[5]

2

2007

M

74

Liposarcoma

t-MDS/t-AML

46,XY,t(1;11)(q23;p15)[17]/46,XY[3]

Doxorubicin, ifosfamide, radiation

Dead

[6]

3

2004

M

42

CML-AP

CML-AP

46,XY,t(1;11)(q21;p15),t(9; 22)(q34;q11)[30]

Hydrea, Myleran

Dead

[7]

4

2004

F

44

Breast carcinoma

t-AML

46,XX,t(1;11)(q25;p15)[17]/46,XX[3]

Adriamycin, Cytoxan, 5-FU, BMT

Dead

[7]

5

2006

M

51

CML-CP

AML (CML BP)

46,XY,t(1;11)(q23;p15),t(9; 22)(q34;q11)

Hydrea; arabinosylcytosine, aclamycin, daunorubicin

[8]

6

2020

M

49

De novo AML

De novo AML

46,XY,t(1;11)(q23;p15)[20]

Idarubicin, cytarabine, BMT

Alive

Current report

  1. NHL non-Hodgkin lymphoma, CML chronic myelogenous leukemia, AP accelerated phase, CP chronic phase, AML acute myeloid leukemia t-AML treatment-related acute myeloid leukemia, MDS myelodysplastic syndrome, BP blast phase, MACOP-B methotrexate with doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin, 5-FU 5-fluorouracil, BMT bone marrow transplant